Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2018

View Archived Issues

Nilotinib regimen feasible in chronic myeloid leukemia blastic phase, acute myeloid leukemia

RAC2 found as novel target in mantle cell lymphoma

FadD32 inhibitors with quinoline scaffold are more stable and have antitubercular activity in mouse

The ABCs of RAF

Scientists gain new insights into function of NLRC3

Novel more soluble ferrostatin-1 analogues inhibiting ferroptosis in vivo

Recruitment ongoing in phase I study of IBI-188

Shenyang Research Institute of Chemical Industry patent reports IDO1 inhibitors

University of Pisa researchers describe GLP-1 receptor agonists

Glucose-lowering agents revealed in Daiichi Sankyo patent

Compounds for treatment of seizure disorders described in Otsuka patent

ChemoCentryx divulges C5aR antagonists

First patient dosed in pivotal phase III PROTECT study of sparsentan

Incyte Corporation initiates phase III FIGHT-302 trial of pemigatinib

Small studies, in the aggregate, yield "robust data" on thrombosis

Sustained clinical benefit in patients with beta-thalassemia following LentiGlobin gene therapy

Novel CD19+CD22 CAR-T cocktail shows safety and efficacy in phase I study

Ibrutinib plus rituximab is superior to conventional chemotherapy for chronic lymphocytic leukemia

Addition of daratumumab to lenalidomide and dexamethasone improves outcome of multiple myeloma

Kyorin Pharmaceutical and Yissum enter respiratory drug development collaboration

JHL initiates phase III trial of rituximab biosimiilar JHL-1101

Bridge Biotherapeutics initiates phase II study of BBT-401

University of Pennsylvania pilot study explores mature dendritic cell vaccine for pancreatic cancer

FDA approves sNDA to expand the age range for Ravicti oral liquid to include newborns

Perlara and Rambam Medical Center enter APOL1 kidney disease partnership

SRS-143 demonstrates promising results in preclinical models of asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...